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Introduction {#s1}
============

Metformin, which belongs to the biguanide class, is one of the most generally used oral hypoglycemic agents. It has been used for more than 50 years and was approved by the US Food and Drug Administration (FDA) in 1994 [@pone.0109878-Bouchoucha1]. Currently, many clinical practice guidelines for patients with type 2 diabetes, including the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the Korean Diabetes Association (KDA), recommend that metformin treatment should begin at the time of diagnosis of diabetes with lifestyle modification in the absence of contraindications [@pone.0109878-American1]--[@pone.0109878-Ko1]. Moreover, metformin is preferentially selected for combination therapy with sulfonylurea or insulin to achieve the glycemic target goal. Thus, the use of metformin has steadily increased worldwide. According to data using the IMS Health National Disease and Therapeutic Index of the U.S., more than 50% of treatment visits before 2012 were associated with metformin [@pone.0109878-Turner1].

Long-term metformin treatment is a known pharmacological cause of vitamin B~12~ deficiency, as was evident within the first 10--12 years [@pone.0109878-Andres1]--[@pone.0109878-deJager1] after it started to be used, and is associated with decreased serum folate concentrations [@pone.0109878-Wile1], [@pone.0109878-Sahin1]. In addition, metformin treatment may be an iatrogenic cause for the exacerbation of peripheral neuropathy in patients with type 2 diabetes who exhibit depressed vitamin B~12~ levels and elevated fasting total homocysteine and methylmalonic acid (MMA) levels [@pone.0109878-Wile1]. This is clinically important because patients with diabetes often suffer from neurological symptoms, such as numbness, paresthesia, and impaired vibration sensation and proprioception. These clinical symptoms can easily be considered symptoms of diabetic peripheral neuropathy, and anticonvulsants or tricyclic antidepressants (TCAs) are frequently used as drugs to control these uncomfortable symptoms. However, the symptoms of vitamin B~12~ deficiency can be easily misunderstood as diabetic peripheral neuropathy, which can lead to unnecessary drug use and misdiagnosis as other demyelinating nerve diseases.

We previously reported a high prevalence of vitamin B~12~ deficiency in patients with type 2 diabetes treated with metformin, particularly in subjects with a longer duration and higher daily dose of metformin use [@pone.0109878-Ko2]. However, most patients with diabetes are not treated with metformin monotherapy for glycemic control, and there have been few studies on the effect of combinations of hypoglycemic agents with metformin on vitamin B~12~ deficiency. Thus, we focused on the effect of combinations of metformin with either sulfonylurea or insulin, which are frequently used hypoglycemic agents, on vitamin B12 deficiency during the same time period.

Thus, the aim of this study was to investigate the effect of sulfonylurea or insulin on vitamin B~12~ deficiency when used as a combinatorial therapy with metformin for patients with type 2 diabetes.

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

This study was performed according to the Declaration of Helsinki and approved by the Institutional Review Board of the Catholic University Medical Centre. Written informed consent was obtained from all of the participants.

Study Design and Subjects {#s2b}
-------------------------

Between January 2012 and April 2014, patients with type 2 diabetes, aged 25 to 80 years, who had taken metformin plus sulfonylurea (S+M group) or metformin plus insulin (I+M group) for at least six months were recruited consecutively at the university-affiliated diabetes center of St. Vincent\'s Hospital in South Korea. To exclude any effects of different treatment periods of sulfonylurea or insulin on the vitamin B~12~ level, we included only those patients who used either insulin plus metformin or sulfonylurea plus metformin during the same time period. A maximum difference of three months of treatment for each combination was allowed for inclusion in this study.

Patients with newly diagnosed type 2 diabetes, type 1 diabetes, pernicious anemia, or decreased renal function (serum creatinine level\>1.7 mg/dL for males or \>1.5 mg/dL for females) and pregnant patients were excluded. Patients with a previous history of vitamin B~12~ injections, gastrectomy, colectomy, inflammatory bowel disease, or chronic heavy alcohol drinker and vegetarians were also excluded. Patients with severe medical illnesses, such as severe infection, sepsis, malignancies, liver cirrhosis, heart failure or renal failure, were also excluded from this study.

The medication history of the enrolled subjects was evaluated using a dietary supplement questionnaire, and the medication history included over-the-counter multivitamins, calcium supplements, histamine-2 receptor blockers (H2 blockers) and proton pump inhibitors (PPIs). To analyze the effects of sulfonylurea dosage on vitamin B~12~ deficiency, we classified the patients into 4 groups according to the dosages of their sulfonylurea regimens as follows: **Group 1**: glimepiride 1 mg, gliclazide 80 mg, gliclazide MR 30 mg, and glibenclamide 5 mg (n = 40); **Group 2**: glimepiride 2 mg, gliclazide 160 mg, gliclazide MR 60 mg, and glibenclamide 10 mg (n = 116); **Group 3**: glimepiride 3 mg, gliclazide 240 mg, gliclazide MR 90 mg, and glibenclamide 15 mg (n = 56); and **Group 4**: glimepiride 4 mg, gliclazide 320 mg, gliclazide MR 120 mg, and glibenclamide 20 mg (n = 87)[@pone.0109878-Schernthaner1], [@pone.0109878-Kimberley1].

The patients were defined "alcohol" drinkers if their average consumption was 1 to 2 drinks per day (\>1 g alcohol/day after converting the average frequency and amount of alcoholic beverages consumed into units of pure alcohol (in grams) consumed per day[@pone.0109878-Agarwal1]. The patients were also divided into current smokers, ex-smokers or non-smokers according to their smoking habits. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or any use of antihypertensive medications [@pone.0109878-Ko3].

Assessments and Outcome Measures {#s2c}
--------------------------------

The primary outcome was biochemical vitamin B~12~ deficiency, which was determined by the serum vitamin B~12~ concentrations. The serum vitamin B~12~ and folate levels were quantified using a chemiluminescent enzyme immunoassay (Immulite 2000; Siemens, Berlin, Germany). We defined biochemical vitamin B~12~ deficiency as serum levels ≤300 pg/mL without folate deficiency [@pone.0109878-Mazokopakis1], [@pone.0109878-Long1]. In the absence of recent anorexia or fasting, a serum folate concentration \<2 ng/mL was diagnostic of folate deficiency. Anemia was defined as Hb \<13 g/dL for males and \<12 g/dL for females based on the WHO guidelines [@pone.0109878-WHOUNICEFUNU1]. The blood glucose level was measured using an automated enzymatic method, and the HbA~1~c level was determined through high-performance liquid chromatography (HPLC-723 G8, Tosoh, Tokyo, Japan). The total cholesterol, triglyceride, and HDL-cholesterol levels were measured enzymatically using an automatic analyzer (Hitachi 736-40, Hitachi, Tokyo, Japan). The measurement of microalbuminuria was performed using immunoturbidimetry (Hitachi 7600-110) through random spot urine collection, and the albumin-to-creatinine ratio (ACR) was calculated. Diabetic nephropathy was defined as ACR≥30 µg/mg creatinine [@pone.0109878-American1]. Diabetic retinopathy was assessed from retinal photographs at baseline, and the findings were reviewed by a board-certified ophthalmologist and classified by the absence or presence of diabetic retinopathy. Diabetic neuropathic symptoms were defined by the presence of typical symptoms, such as pain, burning or aching, prickling sensations, hypoesthesia or numbness in both of the lower legs or feet, through a questionnaire [@pone.0109878-Molitch1]--[@pone.0109878-Meijer1].

Statistical analyses {#s2d}
--------------------

We used SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA) for statistical analyses. The clinical characteristics and parameters are expressed as the means ± standard deviation (SD) or numbers (percentages). Pearson\'s Chi-square tests were used to test the differences in the proportion of categorical variables, and independent *t*-tests were used to evaluate the differences between the means of two continuous variables. One-way ANOVAs were used to evaluate the differences in the means of the continuous variables between the sulfonylurea groups. Pearson correlation analyses were performed to examine the linear relationship between the serum vitamin B~12~ levels and the duration of metformin use. The variables that were found to be statistically significant in the univariable analysis or reported to affect the vitamin B~12~ levels were included in the multivariable analysis. A multivariable logistic regression analysis was performed to assess the independent association of each factor with vitamin B~12~ deficiency. *P* values \<0.05 were considered to be statistically significant.

Results {#s3}
=======

After exclusion during the study period, 394 eligible patients were enrolled and completed the evaluation. The clinical characteristics of the patients are shown in [Table 1](#pone-0109878-t001){ref-type="table"}. Of the 394 patients with type 2 diabetes, the mean age and duration of diabetes were 59.4±10.5 years and 12.2±6.7 years, respectively. In this study, 45.4% of the patients were males, 51.0% had hypertension, and the mean HbA~1~c level was 7.8±1.5% at baseline. The mean vitamin B~12~ level was 638.0±279.6 pg/mL, and 56 patients (14.2%) showed vitamin B~12~ deficiency ([Table 1](#pone-0109878-t001){ref-type="table"}).

10.1371/journal.pone.0109878.t001

###### Baseline clinical characteristics of the subjects.

![](pone.0109878.t001){#pone-0109878-t001-1}

  Characteristic                           Total subjects (n = 394)
  --------------------------------------- --------------------------
  Age (years)                                     59.4±10.5
  Men, n (%)                                      179 (45.4)
  Diabetic duration (years)                        12.2±6.7
  Alcohol (yes, %)                                94 (23.9)
  Smoking (yes, %)                                69 (17.5)
  BMI (kg/m^2^)                                    24.8±3.2
  Hypertension (yes, %)                           201 (51.0)
  Diabetic retinopathy (yes, %)                   109 (27.7)
  Diabetic neuropathic symptom (yes, %)           86 (21.8)
  Diabetic nephropathy (yes, %)                   132 (33.5)
  Duration of metformin use (months)              82.6±49.4
  Daily dose of metformin (mg)                   1305.5±449.4
  Hypertensive medication (yes, %)                242 (61.4)
  Use of statin (yes, %)                          212 (53.8)
  Over-the-counter multivitamin(yes, %)           46 (11.7)
  Calcium supplement (yes, %)                      18 (4.6)
  H2 blocker or PPI (yes, %)                       30 (7.6)
  FBS (mg/dL)                                     145.5±53.9
  Creatinine (mg/dL)                               0.8±0.2
  TC (mg/dL)                                      166.9±37.4
  TG (mg/dL)                                     131.5±115.9
  HDL-cholesterol (mg/dL)                         49.0±23.3
  LDL-cholesterol (mg/dL)                         95.9±40.7
  HbA~1~c (%)                                      7.8±1.5
  Vitamin B~12~ deficiency, n (%)                 56 (14.2)
  Vitamin B~12~ (pg/mL)                          638.0±279.6
  Serum folate (ng/mL)                             9.9±5.7
  Anemia^\*^(yes, %)                              61 (15.5)
  Hemoglobin (g/dL)                                13.9±5.3
  MCV (fL)                                         89.0±5.0
  MCH (fL)                                         30.7±1.8
  MCHC (fL)                                        34.2±1.3

The data are shown as the means (SD) or n (%). ^\*^Hb\<13 g/dL for men and \<12 g/dL for women (WHO guidelines); BMI, body mass index; H2 blocker, histamine 2 receptor blocker; PPI, proton pump inhibitor; FBS, fasting blood sugar; TC, total cholesterol; TG, triglyceride; MCV, mean corpuscular volume; fL, femtoliter.

Among the total population, 299 patients were treated with metformin combined with sulfonylurea (S+M group), and 95 patients were treated with metformin and insulin (I+M group). Compared with the S+M group, the subjects in the I+M group showed a longer diabetic duration, higher BMI, higher prevalence of diabetic retinopathy and nephropathy, and higher HbA~1~c level ([Table 2](#pone-0109878-t002){ref-type="table"}). Remarkably, the mean vitamin B~12~ level was significantly lower in the S+M group compared with the I+M group (600.0±266.5 vs. 757.7±287.6 pg/mL, *P*\<0.001). In addition, the prevalence of vitamin B~12~ deficiency was significantly higher in the S+M group than in the I+M group (17.4 vs. 4.2%, *P*\<0.005). However, the duration of metformin, the daily dose of metformin, and the prevalence of diabetic neuropathic symptoms and anemia were not significantly different between the two groups ([Table 2](#pone-0109878-t002){ref-type="table"}).

10.1371/journal.pone.0109878.t002

###### Characteristics of the subjects according to combination treatment with metformin.

![](pone.0109878.t002){#pone-0109878-t002-2}

  Characteristic                           S+M (n = 299)   I+M (n = 95)   *P* value
  --------------------------------------- --------------- -------------- -----------
  Age (years)                                59.7±10.3      58.2±10.8       .223
  Men, (%)                                  143 (47.8)      36 (37.9)       .091
  Diabetic duration (years)                  11.2±6.3        15.5±7.2      \<.001
  Alcohol (yes, %)                           80 (26.8)      14 (14.7)       .017
  Smoking (yes, %)                           53 (17.7)      16 (16.8)       .741
  BMI (kg/m^2^)                              24.5±3.2        25.5±3.2       .008
  Hypertension (yes, %)                     152 (50.8)      49 (51.6)       .900
  Diabetic retinopathy (yes, %)              67 (22.4)      42 (44.2)      \<.001
  Diabetic neuropathic symptom (yes, %)      64 (21.4)      22 (23.2)       .422
  Diabetic nephropathy (yes, %)              81 (27.1)      51 (53.7)      \<.001
  Duration of metformin use (months)         80.5±47.0      89.1±56.1       .180
  Daily dose of metformin (mg)             1276.1±451.2    1397.9±432.9     .175
  Use of statin (yes, %)                    154 (51.5)      58 (61.1)       .104
  Over-the-counter multivitamin(yes, %)      34 (11.4)      12 (12.6)       .740
  Calcium supplement (yes, %)                14 (4.7)        4 (4.2)        .848
  H2 blocker or PPI (yes, %)                 20 (6.7)       10 (10.5)       .220
  FBS (mg/dL)                               144.6±52.3      148.3±58.9      .582
  Creatinine (mg/dL)                          0.8±0.2        0.8±0.3        .288
  TC (mg/dL)                                168.1±37.0      163.3±38.3      .275
  TG (mg/dL)                                132.4±127.6     128.7±67.0      .789
  HDL-cholesterol (mg/dL)                    50.1±24.3      45.5±19.3       .057
  LDL-cholesterol (mg/dL)                    97.5±42.0      91.0±36.3       .183
  HbA~1~c (%)                                 7.6±1.3        8.7±1.8       \<.001
  Vitamin B~12~ deficiency, n (%)            52 (17.4)       4 (4.2)        .001
  Vitamin B~12~ (pg/mL)                     600.0±266.5    757.7±287.6     \<.001
  Serum folate (ng/mL)                        9.8±5.6        10.3±6.0       .444
  Anemia^\*^(yes, %)                         42 (14.0)      19 (20.0)       .176
  Hemoglobin (g/dL)                          14.1±6.0        13.4±1.8       .318
  MCV (fL)                                   89.1±5.1        89.0±4.4       .949
  MCH (fL)                                   30.7±1.7        30.6±1.8       .551
  MCHC (fL)                                  34.2±1.3        34.2±1.2       .893

The data are presented as the means (SD) or n (%).^\*^Hb\<13 g/dL for men and \<12 g/dL for women (WHO guidelines); BMI, body mass index; H2 blocker, histamine 2 receptor blocker; PPI, proton pump inhibitor; FBS, fasting blood sugar; TC, total cholesterol; TG, triglyceride; MCV, mean corpuscular volume; fL, femtoliter.

S+M: Metformin + Sulfonylurea; I+M: Metformin + Insulin.

The mean vitamin B~12~ levels of the normal B~12~ level group and the vitamin B~12~ deficiency group were 704.5±244.3 pg/mL and 237.0±46.0 pg/mL, respectively (*P*\<0.005). Compared with the subjects without vitamin B~12~ deficiency, the patients with vitamin B~12~ deficiency were older in age, used more sulfonylurea, and had lower levels of HbA~1~c and hemoglobin ([Table 3](#pone-0109878-t003){ref-type="table"}). In addition, the patients with vitamin B~12~ deficiency demonstrated a higher frequency of anemia but not megaloblastic type anemia than the normal vitamin B~12~ level group (26.8% vs. 13.6%, *P* = 0.017).

10.1371/journal.pone.0109878.t003

###### Characteristics of the two selected groups according to vitamin B~12~ deficiency.

![](pone.0109878.t003){#pone-0109878-t003-3}

  Characteristic                           Vitamin B~12~ deficiency (−)   Vitamin B~12~ deficiency (+)   *P* value
  --------------------------------------- ------------------------------ ------------------------------ -----------
  n                                                    338                             56               
  Age (years)                                       58.7±10.4                      63.3±10.3               .003
  Men, (%)                                          156 (46.2)                     23 (41.1)               .563
  Diabetic duration (years)                          12.2±6.9                       12.7±5.5               .548
  Alcohol (yes, %)                                  80 (23.7)                      14 (25.0)               .866
  Smoking (yes, %)                                  60 (17.8)                       9 (16.1)               .826
  BMI (kg/m^2^)                                      24.8±3.3                       24.4±2.9               .330
  Hypertension (yes, %)                             170 (50.3)                     31 (55.4)               .564
  Sulfonylurea use (yes, %)                         244 (72.2)                     52 (92.9)              \<.001
  Insulin use (yes, %)                              91 (26.9)                       4 (7.1)                .001
  Diabetic retinopathy (yes, %)                     97 (28.7)                      12 (21.4)               .332
  Diabetic neuropathic symptom (yes, %)             70 (20.7)                      16 (28.6)               .221
  Diabetic Nephropathy (yes, %)                     117 (34.6)                     15 (26.8)               .287
  Duration of metformin use (months)                79.2±49.5                      102.6±44.5              .001
  Daily dose of metformin (mg)                     1252.8±425.9                   1623.2±459.9            \<.001
  Hypertensive medication (yes, %)                  205 (60.7)                     37 (66.1)               .463
  Use of statin (yes, %)                            179 (53.0)                     33 (58.9)               .470
  Over-the-counter multivitamin(yes, %)             38 (11.2)                       8 (14.3)               .502
  Calcium supplement (yes, %)                        16 (4.7)                       2 (3.6)                1.000
  H2 blocker or PPI (yes, %)                         24 (7.1)                       6 (10.7)               .410
  FBS (mg/dL)                                       146l5±55l4                     139.0±43.2              .248
  Creatinine (mg/dL)                                 0.8±0.2                        0.8±0.2                .685
  TC (mg/dL)                                        168.0±37.7                     160.5±34.8              .145
  TG (mg/dL)                                       131.2±121.9                     133.1±69.6              .869
  HDL-cholesterol (mg/dL)                           49.6±24.1                      45.8±17.4               .160
  LDL-cholesterol (mg/dL)                           96.6±41.6                      92.0±35.1               .379
  HbA~1~c (%)                                        7.9±1.6                        7.4±1.4                .006
  Vitamin B~12~ (pg/mL)                            704.5±244.3                     237.0±46.0             \<.001
  Serum folate (ng/mL)                               9.9±5.7                        9.7±5.6                .747
  Anemia^\*^(yes, %)                                46 (13.6)                      15 (26.8)               .017
  Hemoglobin (g/dL)                                  14.1±5.7                       13.1±1.5               .010
  MCV (fL)                                           89.1±5.1                       89.0±4.2               .800
  MCH (fL)                                           30.8±1.8                       30.4±1.7               .150
  MCHC (fL)                                          34.3±1.2                       33.9±1.7               .106

The data are presented as the means (SD) or n (%).^\*^Hb\<13 g/dL for men and \<12 g/dL for women (WHO guidelines); BMI, body mass index; H2 blocker, histamine 2 receptor blocker; PPI, proton pump inhibitor; FBS, fasting blood sugar; TC, total cholesterol; TG, triglyceride; MCV, mean corpuscular volume; fL, femtoliter.

Of the total subjects involved in the present study, 61 (15.5%) had anemia, and 14 (4.7%) of the patients also had vitamin B~12~ deficiency. Of the patients with B~12~ deficiency, 15 (26.8%) patients were anemic, but 46 (13.6%) of the patients without B~12~ deficiency were anemic (*P* = 0.017, [Table 3](#pone-0109878-t003){ref-type="table"}). Only four of the total subjects (1.02%) had a mean corpuscular volume (MCV)\>100 fL, and only two patients had anemia (Hb 12.4 g/dL in males, Hb 10.4 g/dL in females).

The duration of treatment and daily dose of metformin were significantly higher in the patients with vitamin B~12~ deficiency compared with the patients without vitamin B~12~ deficiency ([Table 3](#pone-0109878-t003){ref-type="table"}). However, the presence of diabetic complications and the duration of diabetes were not different between the two groups.

The correlation between the serum vitamin B~12~ level and the duration of metformin use was evaluated. The vitamin B~12~ levels showed a significant negative correlation with the duration of metformin treatment in the S+M group (R^2^ = 0.049, *P*\<0.001, [Fig. 1A](#pone-0109878-g001){ref-type="fig"}) but not in the I+M group (R^2^ = 0.004, *P* = 0.550, [Fig. 1B](#pone-0109878-g001){ref-type="fig"}).

![Correlation between the vitamin B~12~ levels and the duration of metformin treatment in two different groups.\
A: S+M group, B: I+M group. R^2^: coefficient of determination.](pone.0109878.g001){#pone-0109878-g001}

After adjusting for confounding factors, such as age, sex, diabetic duration, duration and daily dose of metformin treatment, the presence of hypertension or anemia, the HbA~1~c level, and diabetic complications, the multivariable logistic regression analysis revealed that sulfonylurea use was significantly associated with vitamin B~12~ deficiency in patients with type 2 diabetes (OR = 4.74, 95% CI 1.41--15.99, *P* = 0.012, [Table 4](#pone-0109878-t004){ref-type="table"}).

10.1371/journal.pone.0109878.t004

###### Logistic regression analysis for potential risk factors of Vitamin B~12~ deficiency among patients with type 2 diabetes.
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  Risk factor                                       OR (95% CI)        *P* value
  -------------------------------------------- ---------------------- -----------
  Male gender                                    0.63 (0.27--1.48)       .284
  Age (per year)                                 1.05 (1.01--1.09)       .028
  Sulfonylurea use                               4.74 (1.41--15.99)      .012
  Diabetic duration (per year)                   0.93 (0.86--1.00)       .056
  Duration of metformin use (year)                                       .009
  \<5 years                                              1            
  5 to 9 years                                   4.72 (1.82--12.27)      .001
  ≥10 years                                      6.74 (1.94--23.50)      .003
  Daily dose of metformin (mg)                                          \<.001
  \<1000 mg/day                                          1            
  1000 to 1999 mg/day                            3.64 (0.43--30.66)      .234
  ≥2000 mg                                      31.15 (3.44--282.20)     .002
  Use of H2 blocker or Proton pump inhibitor     1.23 (0.39--3.89)       .731
  Over-the-counter multivitamin use              1.39 (0.51--3.77)       .516
  Calcium use                                    0.38 (0.07--2.22)       .282
  HbA~1~c (%)                                    0.74 (0.56--0.99)       .044
  Anemia                                         2.03 (0.87--4.71)       .101

To investigate the effects of the dosage of sulfonylurea on vitamin B~12~ deficiency, we performed further analyses according to the mean daily dosages of sulfonylurea. There were no significant differences between the clinical variables of the patients in each of the four groups at the beginning of the study with the exception of diabetic duration and HbA~1~c level ([Table 5](#pone-0109878-t005){ref-type="table"}). When we classified the patients into four groups according to daily dosages of sulfonylurea, we found that the vitamin B~12~ level was significantly lower in the higher dosage group (Group 4) than in Group 1, *P*\<0.001; [Fig. 2](#pone-0109878-g002){ref-type="fig"}, [Table 5](#pone-0109878-t005){ref-type="table"}). The prevalence of vitamin B~12~ deficiency also increased with increasing sulfonylurea dosage. Compared to Group 1, the percentage of vitamin B~12~ deficiency was approximately 15-fold higher in the patients of Group 4 (2.5% vs. 39.1%, *P*\<0.001, [Table 5](#pone-0109878-t005){ref-type="table"}). Even after adjusting for age, sex, diabetic duration, hypertension, alcohol drinker, duration and daily dose of metformin, hemoglobin level, HbA~1~c level, and presence of anemia in the multivariable logistic regression, this analysis revealed that the highest dosage of sulfonylurea was significantly associated with the presence of vitamin B~12~ deficiency in patients with type 2 diabetes (OR 20.3, 95% CI 2.39--171.9, *P* = 0.006, [Table 6](#pone-0109878-t006){ref-type="table"}).

![The mean value of vitamin B~12~ according to daily sulfonylurea dosage (\* *P*\<0.05 vs. Group 1).\
**Group 1**: glimepiride 1 mg, gliclazide 80 mg, gliclazide MR 30 mg, and glibenclamide 5 mg (n = 40); **Group 2**: glimepiride 2 mg, gliclazide 160 mg, gliclazide MR 60 mg, and glibenclamide 10 mg (n = 116); **Group 3**: glimepiride 3 mg, gliclazide 240 mg, gliclazide MR 90 mg, and glibenclamide 15 mg (n = 56); and **Group 4**: glimepiride 4 mg, gliclazide 320 mg, gliclazide MR 120 mg, and glibenclamide 20 mg (n = 87).](pone.0109878.g002){#pone-0109878-g002}

10.1371/journal.pone.0109878.t005

###### Clinical characteristics according to daily dosage of sulfonylurea.

![](pone.0109878.t005){#pone-0109878-t005-5}

                                        Group 1 (n = 40)   Group 2 (n = 116)   Group 3 (n = 56)   Group 4 (n = 87)   *P* value
  ------------------------------------ ------------------ ------------------- ------------------ ------------------ -----------
  Age                                      59.8±10.5           58.9±10.2          60.6±11.9           60.0±9.8         0.768
  Men, (%)                                 21 (52.5)           57 (49.1)          25 (44.6)          40 (46.0)         0.855
  Diabetic duration (years)                 9.23±5.2           10.6±6.0            12.9±6.0           11.8±6.0         0.017
  Alcohol (yes, %)                          8 (20.0)           40 (34.5)          10 (17.9)          20 (23.0)         0.064
  BMI (kg/m^2^)                             24.1±3.1           24.7±3.4            24.5±2.9           24.5±3.1         0.729
  Hypertension (yes, %)                    26 (65.0)           52 (44.8)          31 (55.4)          37 (42.5)         0.093
  Duration of metformin use (months)       71.1±45.9           73.4±47.0          92.2±45.7          86.7±46.8         0.026
  Daily dose of metformin (mg)            906.3±342.9        1181.0±395.3        1369.6±394.0       1512.6±453.7      \<0.001
  FBS (mg/dL)                              134.1±25.0         138.8±40.8          148.5±57.3         154.9±68.0        0.081
  Creatinine (mg/dL)                        0.79±0.2           0.80±0.2            0.78±0.2           0.83±0.2         0.651
  HbA~1~c (%)                               7.03±0.6           7.47±1.2            7.61±1.2           7.90±1.7         0.006
  Vitamin B~12~ (pg/mL)                   801.8±214.2         647.3±238.9        561.0±216.9        471.3±281.4       \<0.001
  Vitamin B~12~ deficiency (yes, %)         1 (2.5)             9 (7.8)            8 (14.3)          34 (39.1)        \<0.001
  Serum folate (ng/mL)                      11.8±6.3           9.36±5.2            9.78±5.8           9.40±5.5         0.120
  Anemia (yes, %)\*                         3 (7.5)            12 (10.3)          12 (21.4)          15 (17.2)         0.055
  Hemoglobin (g/dL)                        16.7±1.61           13.9±1.4            13.5±1.6           13.5±1.6         0.032

The data are presented as the means (SD) or n (%).^\*^Hb\<13 g/dL for men and \<12 g/dL for women (WHO guidelines); BMI, body mass index; FBS, fasting blood sugar.

**Group 1**; glimepiride 1 mg, gliclazide 80 mg, gliclazide MR 30 mg, glibenclamide 5 mg, **Group 2**; glimepiride 2 mg, gliclazide 160 mg, gliclazide MR 60 mg, glibenclamide 10 mg, **Group 3**; glimepiride 3 mg, gliclazide 240 mg, gliclazide MR 90 mg, glibenclamide 15 mg, **Group 4**; glimepiride 4 mg, gliclazide 320 mg, gliclazide MR 120 mg, glibenclamide 20 mg.

10.1371/journal.pone.0109878.t006

###### Relationship between daily dosage of sulfonylurea regimen and vitamin B~12~ deficiency.

![](pone.0109878.t006){#pone-0109878-t006-6}

               Odds ratio (95% CI)                                           
  ----------- --------------------- ------------------- -------------------- --------------------
  Group 1              1.0                  1.0                 1.0                  1.0
  Group 2       3.46 (0.42--28.5)    4.15 (0.49--34.7)   3.43 (0.40--29.3)    2.68 (0.31--23.3)
  Group 3       6.13 (0.73--51.8)    7.57 (0.88--65.4)   4.67 (0.52--42.2)    3.96 (0.43--36.6)
  Group 4      27.6 (3.57--213.0)    39.5 (4.9--317.0)   23.4 (2.79--195.0)   20.3 (2.39--171.9)
  *P* value          \<0.001              \<0.001             \<0.001              \<0.001

Multivariable logistic regression analysis models were adjusted as follows: model 1: sex, age; model 2: model 1 + diabetes duration, hypertension, HbA~1c~; model 3: model 2 + duration of metformin, daily dose of metformin; model 4: model 3 + alcohol, hemoglobin, presence of anemia.

**Group 1**; glimepiride 1 mg, gliclazide 80 mg, gliclazide MR 30 mg, glibenclamide 5 mg, **Group 2**; glimepiride 2 mg, gliclazide 160 mg, gliclazide MR 60 mg, glibenclamide 10 mg, **Group 3**; glimepiride 3 mg, gliclazide 240 mg, gliclazide MR 90 mg, glibenclamide 15 mg, **Group 4**; glimepiride 4 mg, gliclazide 320 mg, gliclazide MR 120 mg, glibenclamide 20 mg.

Discussion {#s4}
==========

In this study, we found a more significant association between the combined treatment of sulfonylurea plus metformin and a higher prevalence of vitamin B~12~ deficiency in patients with type 2 diabetes compared with that found for the insulin plus metformin combination therapy. We also demonstrated that vitamin B~12~ deficiency was significantly correlated with the duration of metformin use. After adjusting for confounding factors, the sulfonylurea combination was significantly associated with metformin-related vitamin B~12~ deficiency compared with the insulin combination during the same time period. This study provides the first analysis of metformin-associated vitamin B~12~ deficiency in response to combined hypoglycemic medications.

Metformin treatment with lifestyle modifications is generally recommended as the first-line treatment for type 2 diabetes [@pone.0109878-American1]--[@pone.0109878-Ko1]. If the glycemic control status does not reach the target range, additional hypoglycemic medications should be added to the metformin therapy based on the patients\' clinical characteristics. With a steady increase in the number of patients with diabetes, a longer life expectancy of diabetic patients, and the clinical benefits of intensive glycemic control, oral hypoglycemic agents or insulin are consequently expected to be used more often in combination with metformin.

Vitamin B~12~ deficiency is one of the clinically important side effects of metformin treatment. Approximately 6--10% and up to 30% of patients receiving metformin for diabetes treatment have been reported to experience reduced vitamin B~12~ absorption [@pone.0109878-Meijer1]--[@pone.0109878-SparreHermann1], and the serum vitamin B~12~ levels were decreased in 14% to 30% of metformin-treated patients [@pone.0109878-Wile1], [@pone.0109878-Tomkin1], [@pone.0109878-DeFronzo1]. A recent study from the National Health and Nutrition Examination Survey (NHANES) revealed that 5.8% of patients with diabetes using metformin presented with vitamin B~12~ deficiency (serum vitamin B~12~ level ≤200 pg/dL) compared with 2.4% of patients with diabetes not using metformin and 3.3% of patients without diabetes [@pone.0109878-Pflipsen1].

Patients with metformin-induced vitamin B~12~ deficiency exhibit some neurological symptoms, such as paresthesias, impaired vibration sensation and proprioception, which are a potential result of neurological damage. These symptoms may be mistaken as diabetic peripheral neuropathy [@pone.0109878-Bell1].A previous study reported an association between low vitamin B~12~ levels and poor nerve conduction velocities with poorer responses to light touch via monofilament detection [@pone.0109878-Leishear1]. This may lead patients to use unnecessary anticonvulsants or tricyclic antidepressants [@pone.0109878-Bell1], [@pone.0109878-Naha1], [@pone.0109878-Hin1]. Because vitamin B~12~-associated neuropathy is a reversible and treatable condition, the early detection and treatment of vitamin B~12~ deficiency is clinically important in patients with diabetes using metformin [@pone.0109878-Hin1], [@pone.0109878-Kibirige1].

Based on our results, 14.2% of the subjects showed vitamin B~12~ deficiency. The patients treated with metformin plus sulfonylurea (S+M group) showed a significantly higher prevalence of vitamin B~12~ deficiency compared with those treated with metformin plus insulin (I+M group) for the same time period. However, the prevalence of diabetic neuropathic symptoms or anemia was not different between the two groups. In addition, the patients with vitamin B~12~ deficiency were older in age and used metformin for a longer duration and at a higher daily dose; in addition, more patients with vitamin B~12~ deficiency used sulfonylurea, and approximately a two-fold higher number of patients with vitamin B~12~ deficiency had anemia compared with the patients without vitamin B~12~ deficiency. The diabetic duration and the presence of diabetic microvascular complications did not affect vitamin B~12~ deficiency.

Classically, vitamin B~12~ deficiency is related to megaloblastic anemia (MCV\>100 fL) [@pone.0109878-Andres1], [@pone.0109878-Mazokopakis1]. However, the observed mean MCV level in our subjects with vitamin B~12~ deficiency was not greater than 100 fL, and the prevalence of megaloblastic anemia was approximately 0.5% (n = 2). No difference was found in the mean MCV between the groups with and without vitamin B~12~ deficiency. Thus, the anemia was most likely caused from chronic illness. Previous reports have indicated that up to 30% of vitamin B~12~-responsive disorders have normal MCVs [@pone.0109878-Kibirige1]--[@pone.0109878-Wickramasinghe1]. Moreover, the masking of the macrocytic expression of megaloblastic anemia by coexisting thalassaemia, iron deficiency and chronic illness has been widely reported [@pone.0109878-Wickramasinghe1], [@pone.0109878-Chan1]. Thus, investigating the red cell distribution width and the reticulocyte index and the careful examination of the blood using a peripheral blood smear may be helpful for distinguishing vitamin B~12~ deficiency-related anemia from anemia due to other causes [@pone.0109878-Wickramasinghe1], [@pone.0109878-Chan1].

In our study population, 86 participants (21.8%) had typical diabetic neuropathic symptoms. The mean diabetic duration and the duration of metformin treatment were 12.2 years and 82.6 months, respectively. Remarkably, the presence of diabetic neuropathic symptoms was not different between the groups with and without vitamin B~12~ deficiency. Although the duration of use and the daily dose of metformin were correlated with vitamin B~12~ deficiency, a long-standing diabetic duration with long-term metformin use may contribute to this lack of difference in the presence of neuropathic symptoms. In addition, diabetic neuropathy, as suggested by typical symptoms, did not reflect the severity of the diabetic neuropathy despite the presence of vitamin B~12~ deficiency.

There is no known mechanism of metformin-induced vitamin B~12~ deficiency. Some hypotheses include bacterial overgrowth in the small intestine, which has been attributed to diabetes mellitus, changes in small bowel motility, changes in bacterial flora, competitive inhibition or inactivation of vitamin B~12~ absorption, or an effect of calcium on cell membranes [@pone.0109878-Wulffele1]--[@pone.0109878-Bauman1]. Moreover, none of the studies explain the effect of sulfonylurea on vitamin B~12~ metabolism in metformin-induced vitamin B~12~ deficiency. In the present study, we clearly demonstrated that the mean blood vitamin B~12~ level significantly decreased and that the prevalence of vitamin B~12~ deficiency significantly increased with the daily dosage of sulfonylurea in patients with type 2 diabetes. Remarkably, this finding remained significantly after adjustments for the daily dosage and duration of metformin treatment among the patients taking the maximal sulfonylurea dosage. Therefore, we suggest that sulfonylurea, in contrast to insulin, might affect intestinal vitamin B~12~ absorption or metabolism when combined with metformin particularly in patients taking the maximal dosage for extended periods.

There are some limitations to this study. First, this hospital-based cross-sectional study included a small number of patients with relatively long-standing diabetes. In addition, the assessment of typical diabetic neuropathic symptoms may make it difficult to observe the effect of vitamin B~12~deficiency on diabetic neuropathy. Second, we did not measure the MMA, homocysteine or iron levels. These laboratory examinations could not be performed routinely on an outpatient basis. Finally, this cohort study consisted entirely of an Asian population. Thus, additional studies are required to apply this finding to other ethnic groups.

In conclusion, our data suggested the need for regular vitamin B~12~ monitoring in patients with type 2 diabetes, particularly patients receiving higher daily dosage of sulfonylurea plus metformin treatment for a long time period, even in the absence of hematological abnormalities. Further evaluation is needed to clarify the pathological mechanisms and clinical recommendations for B~12~ supplementation for patients with prolonged metformin therapy in the future.
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